News

The product monograph change will help enable individual benefit risk assessment for MS patients. The new label identifies anti-JCV antibody status as a risk factor for developing an

The antibacterial oxazolidinone targets infections due to multi-drug resistant Gram-positive pathogens. MicuRx president and chief executive officer Zhengyu Yuan said, "With a scarcity of new antibiotics in development

The new release includes more than 94,500 gene entries, displays about 52,000 non-protein-coding RNA genes and also shows considerably expanded tissue proteome abundance diagrams. LifeMap Sciences president and

The company has even filed an application with European marketing authorization for regorafenib for the treatment of patients with mCRC. The submission is based on the results of

The company plans to expand the product category with antibodies against Alemtuzumab (Campath), Bevacizumab (Avastin), Infliximab (Remicade), Ustekinumab (Stelara) and Adalimumab (Humira) shortly. AbD Serotec head Dieter Feger

The company has launched Suprenza ODT in 15mg and 30mg dosage strengths. Suprenza is a sympathomimetic amine anorectic indicated for patients with an initial body mass index of

The companies will collaborate in marker discovery and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). Financial terms of the

The generic version of Boehringer Ingelheim’s Viramune is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection. Mylan CEO Heather Bresch said the launch of Nevirapine Tablets, 200mg,

Alnylam has received world-wide, non-exclusive license to the Baulcombe patent from PBL for use in the field of human therapeutics. Both the companies have kept the financial terms